{"id":"W2884754452","doi":"10.1177/1352458518789884","title":"Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study","year":2018,"lang":"en","type":"article","venue":"Multiple Sclerosis Journal","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"ca_institutions":"St. Michael's Hospital; McGill University; NeuroRx Research (Canada)","funders":"Bayer HealthCare; CSL Behring; IC Design Education Center; Teva Pharmaceutical Industries; Biogen; Sanofi; European Commission; Pfizer","keywords":"Medicine; Placebo; Tolerability; Internal medicine; Adverse effect; Pathology; Alternative medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007161097,0.00288702,0.004316667,0.0007410577,0.000809965,0.001233016,0.001442964,0.002944725,0.007124032],"category_scores_gemma":[0.005218658,0.001259527,0.002539584,0.0006331076,0.001475833,0.001526361,0.000653175,0.002973486,0.00153243],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009722363,"about_ca_system_score_gemma":0.002414129,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005574437,"about_ca_topic_score_gemma":0.001240916,"domain_scores_codex":[0.9968902,0.001870702,0.0002396387,0.0004158905,0.0002820765,0.0003013562],"domain_scores_gemma":[0.9958529,0.0009119136,0.001289095,0.0005899442,0.0005638141,0.0007923681],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9683443,0.01690949,0.0005288107,0.000356709,0.000529594,0.00002655037,0.00006269241,0.0001941168,0.004306353,0.00005332055,0.0005375182,0.008150447],"study_design_scores_gemma":[0.9035905,0.09353811,0.001231503,0.00002206095,0.0002302943,0.00002391982,0.00001094823,0.0002085012,0.0005662802,0.00006797203,0.0004978029,0.00001215788],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9540488,0.002334599,0.002641344,0.0006824692,0.0006786422,0.03505166,0.002210545,0.0002842931,0.00206769],"genre_scores_gemma":[0.9337274,0.002293968,0.007058778,0.001452381,0.001010465,0.04740662,0.002319826,0.00007197793,0.004658651],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007161097,"threshold_uncertainty_score":0.03787196,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1724768760353528,"score_gpt":0.3608088688963201,"score_spread":0.1883319928609673,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}